Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, aims to regulate the quality and safety of therapeutic goods, ensuring they meet necessary standards before being marketed and supplied. This Act was introduced to address gaps in the oversight and regulation of therapeutic goods, providing a comprehensive framework for their control, thereby protecting public health. The Therapeutic Goods Administration, a branch of the Department of Health, administers this Act and its provisions. The policy objective underpinning this legislation is to safeguard the health and safety of the Australian population by ensuring that therapeutic goods available in the market are of high quality and meet the necessary safety and efficacy standards. The Act grants the Secretary of the Department of Health the authority to license manufacturers of therapeutic goods, as demonstrated by the recent publication of licenses granted to several companies including Scental Pacific Pty Ltd, The Australian Red Cross Blood Service, PureIV, and others.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health, applies to entities that are involved in the manufacture of therapeutic goods within Australia. This legislation pertains to the regulation of the manufacturing processes and the quality control of therapeutic goods, which include medicines, medical devices, blood and blood components, and other health-related products. The Act provides the legal framework for granting licences to manufacturers who meet the specified regulatory standards, ensuring that therapeutic goods are safe, of high quality, and effective. The scope of the Act extends nationally, affecting all manufacturers operating within Australia, irrespective of their location within the states or territories. However, it is important to note that certain exclusions and exemptions may apply, such as for products that are manufactured solely for personal use or research purposes. The Act also provides for the possibility of extending its application through subordinate instruments, which may include regulations and guidelines that further define the requirements and standards for manufacturing therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") sets out the regulatory framework for therapeutic goods in Australia, including the licensing of manufacturers. Under section 38 of the Act, the Secretary can grant a Licence to Manufacture Therapeutic Goods to an entity, allowing them to manufacture such goods. The Licence is essential for entities to legally produce therapeutic goods, which include medicines, medical devices, and other health-related products. The published list includes various companies, each granted a specific licence number and location, such as Sental Pacific Pty Ltd (Licence No. MI-2018-LI-11433-1), The Australian Red Cross Blood Service (Licence No. MI-2019-LI-07241-1), and PureIV (Licence No. MI-2019-LI-02208-1), among others. Entities granted a Licence to Manufacture Therapeutic Goods are subject to a series of obligations and requirements to ensure compliance with the Act. These include maintaining appropriate quality systems and controls, ensuring that their manufacturing processes meet the necessary standards, and adhering to good manufacturing practices. The licence holders must also ensure that their products are safe, of high quality, and effective for their intended use. Additionally, they are required to keep records and provide documentation as necessary for inspections and audits by the Therapeutic Goods Administration (TGA). Regular reporting and updates to the TGA about changes in manufacturing processes or products are also part of the obligations. Breach of the provisions of the Therapeutic Goods Act 1989 can lead to various civil and criminal consequences. For example, manufacturing therapeutic goods without a valid licence constitutes an offence under the Act. Penalties for such offences can include fines and, in some cases, imprisonment. Specifically, under section 42AA of the Act, an individual can be fined up to $66,000 or, in the case of a body corporate, up to $330,000 for offences related to the manufacture of therapeutic goods without a licence. Furthermore, the TGA can take action to suspend or cancel a licence if it finds non-compliance with the Act's requirements, which can significantly impact the entity's ability to operate in the therapeutic goods market.